Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography

The recruitment status of this study is unknown because the information has not been verified recently.

Verified April 2005 by National Taiwan University Hospital. Recruitment status was Recruiting

First Received on September 8, 2005. Last Updated on November 25, 2005 History of Changes

Sponsor:	National Taiwan University Hospital
Information provided by:	National Taiwan University Hospital
ClinicalTrials.gov Identifier:	NCT00155376

Purpose

Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.

Condition	Intervention	Phase
Liver Disease	Drug: morphine and glucagon	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Diagnostic

Resource links provided by NLM:

MedlinePlus related topics: Liver Diseases

Drug Information available for: Glucagon Glucagon-like peptide 1

U.S. FDA Resources

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:

MRCP visibility

Estimated Enrollment:	100
Study Start Date:	September 2005
Estimated Study Completion Date:	September 2005

Detailed Description:

Eligibility

Ages Eligible for Study:	20 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

normal volunteer
living liver donor

Exclusion Criteria:

COPD
chronic liver disease
hypersensitive to glucagon
DM
insulinoma
glucagonoma
pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00155376

Contacts

Contact: Yuan-Heng Mo, MD

jamesmyh@ha.mc.ntu.edu.tw

Locations

Taiwan
National Taiwan University Hospital	Recruiting
Taipei, province of Taiwan, Taiwan, 100
Contact: Yuan-Heng Mo, MD jamesmyh@ha.mc.ntu.edu.tw

Sponsors and Collaborators

National Taiwan University Hospital

Investigators

Study Chair:

Hon-Man Liu, MD

National Taiwan University Hospital

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00155376 History of Changes
Other Study ID Numbers:	940104
Study First Received:	September 8, 2005
Last Updated:	November 25, 2005
Health Authority:	Taiwan: Department of Health

Additional relevant MeSH terms:

Liver Diseases
Digestive System Diseases
Glucagon
Glucagon-Like Peptide 1
Morphine
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Gastrointestinal Agents

Therapeutic Uses
Incretins
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Central Nervous System Depressants
Narcotics

ClinicalTrials.gov processed this record on February 09, 2012